Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy

Elisa Tassinari,1 Veronica Mollica,1 Giacomo Nuvola,1 Andrea Marchetti,1 Matteo Rosellini,1 Francesco Massari1,2 1Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 2Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospita...

Full description

Bibliographic Details
Main Authors:	Tassinari E, Mollica V, Nuvola G, Marchetti A, Rosellini M, Massari F
Format:	Article
Language:	English
Published:	Dove Medical Press 2022-06-01
Series:	Cancer Management and Research
Subjects:	urothelial carcinoma immunotherapy immune-checkpoint inhibitors fgfr inhibitor antibody-drug conjugates.
Online Access:	https://www.dovepress.com/treatment-options-for-metastatic-urothelial-carcinoma-after-first-line-peer-reviewed-fulltext-article-CMAR

Similar Items

Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
by: Veronica Mollica, et al.
Published: (2020-06-01)

Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?
by: Marco Audisio, et al.
Published: (2022-05-01)

Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis
by: Alessandro Rizzo, et al.
Published: (2022-02-01)

Emerging strategy for the treatment of urothelial carcinoma: Advances in antibody-drug conjugates combination therapy
by: Xiangyun You, et al.
Published: (2024-02-01)

Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2020-01-01)

Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab
by: Chiang RS, et al.
Published: (2022-10-01)

Current and Emerging Strategies to Treat Urothelial Carcinoma
by: Berkha Rani, et al.
Published: (2023-10-01)

Novel immunotherapy in the management of advanced urothelial cancer - review of the literature
by: Paulina Chmiel, et al.
Published: (2022-08-01)

Immune Checkpoints Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials
by: Hsiao-Ling Chen, et al.
Published: (2021-03-01)

Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer
by: Li-Yu Yang, et al.
Published: (2024-03-01)

Progress in immune checkpoint inhibitor-based combined regimens in the treatment of metastatic urothelial carcinoma
by: Liu Jianbing, Yue Zhongjin, Shang Panfeng, Liu Yating, Chang Hong
Published: (2023-09-01)

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis
by: Keren Rouvinov, et al.
Published: (2023-05-01)

Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma
by: Alexander Chehrazi-Raffle, et al.
Published: (2021-02-01)

Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation
by: Shibin Zhu, et al.
Published: (2022-10-01)

Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review
by: Huang-Yu Yang, et al.
Published: (2020-11-01)

Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy—A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin
by: Susanne Deininger, et al.
Published: (2021-06-01)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
by: Jun Kamei, et al.
Published: (2022-05-01)

Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions
by: Yuki Endo, et al.
Published: (2024-01-01)

Research Progress on the Effect of Clinical Concomitant Medication on Efficacy of Immune Checkpoint Inhibitors in Urothelial Carcinoma
by: LYU Zhengqin, et al.
Published: (2024-03-01)

Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions
by: Jonathan Thouvenin, et al.
Published: (2021-08-01)

Prognostic Factors of Platinum-Refractory Advanced Urothelial Carcinoma Treated with Pembrolizumab
by: Yasunori Akashi, et al.
Published: (2023-12-01)

Upper Tract Urothelial Carcinoma: A Rare Malignancy with Distinct Immuno-Genomic Features in the Era of Precision-Based Therapies
by: Konstantinos Evmorfopoulos, et al.
Published: (2023-06-01)

Changes in the treatment landscape for metastatic urothelial cancer: current therapy and future directions
by: Sang Hoon Yeon, et al.
Published: (2022-05-01)

Prognostic Value and Clinical Significance of FGFR Genomic Alterations (GAs) in Metastatic Urothelial Cancer Patients
by: Elena Sevillano Fernández, et al.
Published: (2022-08-01)

Current Landscape of Immune Checkpoint Inhibitors for Metastatic Urothelial Carcinoma: Is There a Role for Additional T-Cell Blockade?
by: Vanessa Ogbuji, et al.
Published: (2023-12-01)

Immunotherapy with or without targeted therapy for metastatic upper tract urothelial carcinoma: case report and literature review
by: Kangxin Ni, et al.
Published: (2023-05-01)

Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma
by: Andrew B. Katims, et al.
Published: (2022-11-01)

An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT
by: Veronica Mollica, et al.
Published: (2021-12-01)

Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
by: Sara Elena Rebuzzi, et al.
Published: (2021-11-01)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
by: Brigida Anna Maiorano, et al.
Published: (2023-09-01)

Genomics and Immunomics in the Treatment of Urothelial Carcinoma
by: Veronica Mollica, et al.
Published: (2022-05-01)

Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder
by: Sandra van Wilpe, et al.
Published: (2020-09-01)

The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy
by: Tsung-Han Tsai, et al.
Published: (2023-09-01)

Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context
by: Hoffman-Censits J, et al.
Published: (2022-12-01)

Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
by: Pei-Fei Liao, et al.
Published: (2023-11-01)

TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma
by: Elodie Coquan, et al.
Published: (2022-11-01)

Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
by: Alessandro Rizzo, et al.
Published: (2022-08-01)

Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma
by: Nobuaki Matsubara, et al.
Published: (2023-02-01)

Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates
by: Víctor Albarrán, et al.
Published: (2022-10-01)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
by: Utpal Kumar, et al.
Published: (2022-06-01)